The Pivotal Role of Protein Phosphatase 2A (PP2A) in Brain Tumors. 2022

Laura Cucinotta, and Alessia Filippone, and Giovanna Casili, and Marika Lanza, and Valentina Bova, and Anna Paola Capra, and Raffaella Giuffrida, and Cristina Colarossi, and Dorotea Sciacca, and Irene Paterniti, and Salvatore Cuzzocrea, and Michela Campolo, and Emanuela Esposito
Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D'Alcontres, 31-98166 Messina, Italy.

Protein phosphatase 2A (PP2A) is a highly complex heterotrimeric Ser/Thr phosphatase that regulates many cellular processes. PP2A is dysregulated in several human diseases, including oncological pathology; interestingly, PP2A appears to be essential for controlling cell growth and may be involved in cancer development. The role of PP2A as a tumor suppressor has been extensively studied and reviewed. To leverage the potential clinical utility of combination PP2A inhibition and radiotherapy treatment, it is vital that novel highly specific PP2A inhibitors be developed. In this review, the existing literature on the role of PP2A in brain tumors, especially in gliomas and glioblastoma (GBM), was analyzed. Interestingly, the review focused on the role of PP2A inhibitors, focusing on CIP2A inhibition, as CIP2A participated in tumor cell growth by stimulating cell-renewal survival, cellular proliferation, evasion of senescence and inhibition of apoptosis. This review suggested CIP2A inhibition as a promising strategy in oncology target therapy.

UI MeSH Term Description Entries
D001932 Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. Brain Cancer,Brain Metastases,Brain Tumors,Cancer of Brain,Malignant Primary Brain Tumors,Neoplasms, Intracranial,Benign Neoplasms, Brain,Brain Neoplasm, Primary,Brain Neoplasms, Benign,Brain Neoplasms, Malignant,Brain Neoplasms, Malignant, Primary,Brain Neoplasms, Primary Malignant,Brain Tumor, Primary,Brain Tumor, Recurrent,Cancer of the Brain,Intracranial Neoplasms,Malignant Neoplasms, Brain,Malignant Primary Brain Neoplasms,Neoplasms, Brain,Neoplasms, Brain, Benign,Neoplasms, Brain, Malignant,Neoplasms, Brain, Primary,Primary Brain Neoplasms,Primary Malignant Brain Neoplasms,Primary Malignant Brain Tumors,Benign Brain Neoplasm,Benign Brain Neoplasms,Benign Neoplasm, Brain,Brain Benign Neoplasm,Brain Benign Neoplasms,Brain Cancers,Brain Malignant Neoplasm,Brain Malignant Neoplasms,Brain Metastase,Brain Neoplasm,Brain Neoplasm, Benign,Brain Neoplasm, Malignant,Brain Neoplasms, Primary,Brain Tumor,Brain Tumors, Recurrent,Cancer, Brain,Intracranial Neoplasm,Malignant Brain Neoplasm,Malignant Brain Neoplasms,Malignant Neoplasm, Brain,Neoplasm, Brain,Neoplasm, Intracranial,Primary Brain Neoplasm,Primary Brain Tumor,Primary Brain Tumors,Recurrent Brain Tumor,Recurrent Brain Tumors,Tumor, Brain
D005909 Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures. Astrocytoma, Grade IV,Giant Cell Glioblastoma,Glioblastoma Multiforme,Astrocytomas, Grade IV,Giant Cell Glioblastomas,Glioblastoma, Giant Cell,Glioblastomas,Glioblastomas, Giant Cell,Grade IV Astrocytoma,Grade IV Astrocytomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001324 Autoantigens Endogenous tissue constituents with the ability to interact with AUTOANTIBODIES and cause an immune response. Autoantigen,Autologous Antigen,Autologous Antigens,Self-Antigen,Self-Antigens,Antigen, Autologous,Antigens, Autologous,Self Antigen,Self Antigens
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular
D054648 Protein Phosphatase 2 A phosphoprotein phosphatase subtype that is comprised of a catalytic subunit and two different regulatory subunits. At least two genes encode isoforms of the protein phosphatase catalytic subunit, while several isoforms of regulatory subunits exist due to the presence of multiple genes and the alternative splicing of their mRNAs. Protein phosphatase 2 acts on a broad variety of cellular proteins and may play a role as a regulator of intracellular signaling processes. PPP2CA Phosphatase,PPP2CB Phosphatase,Protein Phosphatase 2, Catalytic Subunit,Protein Phosphatase 2, Catalytic Subunit, alpha Isoform,Protein Phosphatase 2, Catalytic Subunit, beta Isoform,Protein Phosphatase 2, Regulatory Subunit,Protein Phosphatase 2, Regulatory Subunit A, alpha Isoform,Protein Phosphatase 2, Regulatory Subunit A, beta Isoform,Protein Phosphatase 2, Regulatory Subunit B, alpha Isoform,Protein Phosphatase 2, Regulatory Subunit B, beta Isoform,Protein Phosphatase 2, Regulatory Subunit B, delta Isoform,Protein Phosphatase 2, Regulatory Subunit B, gamma Isoform,Protein Phosphatase 2A, Catalytic Subunit, alpha Isoform,Protein Phosphatase 2A, Catalytic Subunit, beta Isoform,Protein Phosphatase 2A, Regulatory Subunit A , alpha Isoform,Protein Phosphatase 2A, Regulatory Subunit A, beta Isoform,Protein Phosphatase 2A, Regulatory Subunit B, alpha Isoform,Protein Phosphatase 2A, Regulatory Subunit B, beta Isoform,Protein Phosphatase 2A, Regulatory Subunit B, delta Isoform,Protein Phosphatase 2A, Regulatory Subunit B, gamma Isoform,Protein Phosphatase-2A,Serine Threonine Protein Phosphatase 2A Catalytic Subunit beta Isoform,Serine-Threonine-Protein Phosphatase 2A Catalytic Subunit alpha Isoform,Phosphatase, PPP2CA,Phosphatase, PPP2CB,Protein Phosphatase 2A,Serine Threonine Protein Phosphatase 2A Catalytic Subunit alpha Isoform

Related Publications

Laura Cucinotta, and Alessia Filippone, and Giovanna Casili, and Marika Lanza, and Valentina Bova, and Anna Paola Capra, and Raffaella Giuffrida, and Cristina Colarossi, and Dorotea Sciacca, and Irene Paterniti, and Salvatore Cuzzocrea, and Michela Campolo, and Emanuela Esposito
August 2021, Biochemical Society transactions,
Laura Cucinotta, and Alessia Filippone, and Giovanna Casili, and Marika Lanza, and Valentina Bova, and Anna Paola Capra, and Raffaella Giuffrida, and Cristina Colarossi, and Dorotea Sciacca, and Irene Paterniti, and Salvatore Cuzzocrea, and Michela Campolo, and Emanuela Esposito
August 2023, Biochemical and biophysical research communications,
Laura Cucinotta, and Alessia Filippone, and Giovanna Casili, and Marika Lanza, and Valentina Bova, and Anna Paola Capra, and Raffaella Giuffrida, and Cristina Colarossi, and Dorotea Sciacca, and Irene Paterniti, and Salvatore Cuzzocrea, and Michela Campolo, and Emanuela Esposito
December 2016, Journal of molecular and cellular cardiology,
Laura Cucinotta, and Alessia Filippone, and Giovanna Casili, and Marika Lanza, and Valentina Bova, and Anna Paola Capra, and Raffaella Giuffrida, and Cristina Colarossi, and Dorotea Sciacca, and Irene Paterniti, and Salvatore Cuzzocrea, and Michela Campolo, and Emanuela Esposito
January 2005, Molecular and cellular biochemistry,
Laura Cucinotta, and Alessia Filippone, and Giovanna Casili, and Marika Lanza, and Valentina Bova, and Anna Paola Capra, and Raffaella Giuffrida, and Cristina Colarossi, and Dorotea Sciacca, and Irene Paterniti, and Salvatore Cuzzocrea, and Michela Campolo, and Emanuela Esposito
March 2018, The international journal of biochemistry & cell biology,
Laura Cucinotta, and Alessia Filippone, and Giovanna Casili, and Marika Lanza, and Valentina Bova, and Anna Paola Capra, and Raffaella Giuffrida, and Cristina Colarossi, and Dorotea Sciacca, and Irene Paterniti, and Salvatore Cuzzocrea, and Michela Campolo, and Emanuela Esposito
May 2017, Scientific reports,
Laura Cucinotta, and Alessia Filippone, and Giovanna Casili, and Marika Lanza, and Valentina Bova, and Anna Paola Capra, and Raffaella Giuffrida, and Cristina Colarossi, and Dorotea Sciacca, and Irene Paterniti, and Salvatore Cuzzocrea, and Michela Campolo, and Emanuela Esposito
January 2003, The Journal of biological chemistry,
Laura Cucinotta, and Alessia Filippone, and Giovanna Casili, and Marika Lanza, and Valentina Bova, and Anna Paola Capra, and Raffaella Giuffrida, and Cristina Colarossi, and Dorotea Sciacca, and Irene Paterniti, and Salvatore Cuzzocrea, and Michela Campolo, and Emanuela Esposito
June 2008, Cancer metastasis reviews,
Laura Cucinotta, and Alessia Filippone, and Giovanna Casili, and Marika Lanza, and Valentina Bova, and Anna Paola Capra, and Raffaella Giuffrida, and Cristina Colarossi, and Dorotea Sciacca, and Irene Paterniti, and Salvatore Cuzzocrea, and Michela Campolo, and Emanuela Esposito
March 2000, The Journal of biological chemistry,
Laura Cucinotta, and Alessia Filippone, and Giovanna Casili, and Marika Lanza, and Valentina Bova, and Anna Paola Capra, and Raffaella Giuffrida, and Cristina Colarossi, and Dorotea Sciacca, and Irene Paterniti, and Salvatore Cuzzocrea, and Michela Campolo, and Emanuela Esposito
May 2007, Archives of biochemistry and biophysics,
Copied contents to your clipboard!